Emcure Pharmaceuticals Ltd vs Kilitch Drugs India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1685 as of 18 May 15:30 . The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 years The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The revenue of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 90.1 crore as compare to the Dec '25 revenue of ₹ 55.34 crore. This represent the growth of 62.81% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The ebitda of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 22.64 crore as compare to the Dec '25 ebitda of ₹ 7.68 crore. This represent the growth of 194.79% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 14.88 crore over 8 quarters. This represents a CAGR of 1063.07% The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Kilitch Drugs (India) Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 32,324 Cr while Market cap of Kilitch Drugs (India) Ltd is 534 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd?

As of May 18, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1704.95. On the other hand, Kilitch Drugs (India) Ltd stock price is INR ₹153.0.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Kilitch Drugs (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.